Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels

2009 ◽  
Vol 24 (5) ◽  
pp. 473-482 ◽  
Author(s):  
Derek J Hausenloy ◽  
Derek M Yellon
Circulation ◽  
2020 ◽  
Vol 142 (7) ◽  
pp. 657-669 ◽  
Author(s):  
Kavisha Singh ◽  
Alvin Chandra ◽  
Thomas Sperry ◽  
Parag H. Joshi ◽  
Amit Khera ◽  
...  

Background: High-density lipoprotein (HDL) cholesterol concentration (HDL-C) is an established atheroprotective marker, in particular for coronary artery disease; however, HDL particle concentration (HDL-P) may better predict risk. The associations of HDL-C and HDL-P with ischemic stroke and myocardial infarction (MI) among women and Blacks have not been well studied. We hypothesized that HDL-P would consistently be associated with MI and stroke among women and Blacks compared with HDL-C. Methods: We analyzed individual-level participant data in a pooled cohort of 4 large population studies without baseline atherosclerotic cardiovascular disease: DHS (Dallas Heart Study; n=2535), ARIC (Atherosclerosis Risk in Communities; n=1595), MESA (Multi-Ethnic Study of Atherosclerosis; n=6632), and PREVEND (Prevention of Renal and Vascular Endstage Disease; n=5022). HDL markers were analyzed in adjusted Cox proportional hazard models for MI and ischemic stroke. Results: In the overall population (n=15 784), HDL-P was inversely associated with the combined outcome of MI and ischemic stroke, adjusted for cardiometabolic risk factors (hazard ratio [HR] for quartile 4 [Q4] versus quartile 1 [Q1], 0.64 [95% CI, 0.52–0.78]), as was HDL-C (HR for Q4 versus Q1, 0.76 [95% CI, 0.61–0.94]). Adjustment for HDL-C did not attenuate the inverse relationship between HDL-P and atherosclerotic cardiovascular disease, whereas adjustment for HDL-P attenuated all associations between HDL-C and events. HDL-P was inversely associated with the individual end points of MI and ischemic stroke in the overall population, including in women. HDL-P was inversely associated with MI among White participants but not among Black participants (HR for Q4 versus Q1 for Whites, 0.49 [95% CI, 0.35–0.69]; for Blacks, 1.22 [95% CI, 0.76–1.98]; P interaction =0.001). Similarly, HDL-C was inversely associated with MI among White participants (HR for Q4 versus Q1, 0.53 [95% CI, 0.36–0.78]) but had a weak direct association with MI among Black participants (HR for Q4 versus Q1, 1.75 [95% CI, 1.08–2.83]; P interaction <0.0001). Conclusions: Compared with HDL-C, HDL-P was consistently associated with MI and ischemic stroke in the overall population. Differential associations of both HDL-C and HDL-P for MI by Black ethnicity suggest that atherosclerotic cardiovascular disease risk may differ by vascular domain and ethnicity. Future studies should examine individual outcomes separately.


2021 ◽  
pp. 1-16
Author(s):  
Ato Kwamena Tetteh ◽  
Barbara Araba Yankey ◽  
Ike Solomon Okosun

Background/Aims Cardiovascular disease risk is increased in individuals with various anthropometric measurements and indices. This study estimated linear trends of cardiovascular disease risk and its association with selected anthropometric measurements. Methods: Bi-annual data from 2007-16 (n=26 201) was obtained from the National Health and Nutrition Examination Survey. Cardiovascular disease risk in this study was assessed as total cholesterol to high-density lipoprotein ratio. We used the multiple linear regression analysis procedures to estimate anthropometric variables that best predict cardiovascular disease risk. Results The mean total cholesterol to high-density lipoprotein ratio for the studied population was 4.0 (95% confidence interval: 3.8-4.2). There was a decrease of 0.05 in mean cardiovascular disease risk bi-annually from 4.1 in 2007-8 to 3.9 in 2015-16 (t=-3.27; P=0.0467). The percentage with desirable cardiovascular disease risk decreased by 0.07 bi-annually from 0.42% in 2007-8 to 0.1% in 2015-16 (P=0.0689). Borderline risk increased by 0.8 bi-annually from 90.7% in 2007-8 to 93.8% in 2015-16 (P=0.1176). High cardiovascular disease risk decreased by 0.7 from 8.9% in 2007-8 to 6.2% in 2015-16 (t=-1.95; P=0.1464). Cardiovascular disease risk was consistently higher in males than females for all the cohorts (P<0.0001). The risk was high among the 30-69 years age group but declined after the age of 70 years. Overall, waist circumference, weight and the waist circumference*weight interaction term, adjusted for age, gender, and race/ethnicity, significantly helped to predict cardiovascular disease risk (P<0.0001). Conclusions The majority of the studied population had either borderline or high risk for cardiovascular diseases based on the total cholesterol/high-density lipoprotein ratio. The study findings suggest the need to intensify existing primary prevention efforts to minimise risk and avert cardiovascular disease progression.


Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 554
Author(s):  
Susana Coimbra ◽  
Flávio Reis ◽  
Maria João Valente ◽  
Susana Rocha ◽  
Cristina Catarino ◽  
...  

Dyslipidemia is a major traditional risk factor for cardiovascular disease (CVD) in chronic kidney disease (CKD) patients, although the altered lipid profile does not explain the number and severity of CVD events. High-density lipoprotein (HDL) is a heterogeneous (size, composition, and functionality) population of particles with different atherogenic or atheroprotective properties. HDL-cholesterol concentrations per se may not entirely reflect a beneficial or a risk profile for CVD. Large HDL in CKD patients may have a unique proteome and lipid composition, impairing their cholesterol efflux capacity. This lack of HDL functionality may contribute to the paradoxical coexistence of increased large HDL and enhanced risk for CVD events. Moreover, CKD is associated with inflammation, oxidative stress, diabetes, and/or hypertension that are able to interfere with the anti-inflammatory, antioxidative, and antithrombotic properties of HDL subpopulations. How these changes interfere with HDL functions in CKD is still poorly understood. Further studies are warranted to fully clarify if different HDL subpopulations present different functionalities and/or atheroprotective effects. To achieve this goal, the standardization of techniques would be valuable.


2016 ◽  
Vol 22 (4) ◽  
pp. 897-910 ◽  
Author(s):  
Robert C Block ◽  
Amir Abdolahi ◽  
Christopher P Niemiec ◽  
C Scott Rigby ◽  
Geoffrey C Williams

There is a lack of research on the use of electronic tools that guide patients toward reducing their cardiovascular disease risk. We conducted a 9-month clinical trial in which participants who were at low (n = 100) and moderate (n = 23) cardiovascular disease risk—based on the National Cholesterol Education Program III’s 10-year risk estimator—were randomized to usual care or to usual care plus use of an Interactive Cholesterol Advisory Tool during the first 8 weeks of the study. In the moderate-risk category, an interaction between treatment condition and Framingham risk estimate on low-density lipoprotein and non-high-density lipoprotein cholesterol was observed, such that participants in the virtual clinician treatment condition had a larger reduction in low-density lipoprotein and non-high-density lipoprotein cholesterol as their Framingham risk estimate increased. Perceptions of the Interactive Cholesterol Advisory Tool were positive. Evidence-based information about cardiovascular disease risk and its management was accessible to participants without major technical challenges.


Sign in / Sign up

Export Citation Format

Share Document